MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Acute movement disorders in Tunisian childhood

    H. Benrhouma, H. Klaa, A. Nasri, I. Kraoua, I. Turki (Tunis, Tunisia)

    Objective: To describe clinical, imaging and therapeutic features in 80 children with acute movement disorders. Background: Acute movement disorders are usually misdiagnosed in childhood. Our…
  • 2016 International Congress

    Profile of urgent care visits in movement disorders

    J.T. Lazarus, V.D. Sharma, L. Scorr, S. Factor (Atlanta, GA, USA)

    Objective: To assess the spectrum of clinical complaints and disorders at an Urgent Care Movement Disorders clinic. Background: Movement disorders patients not infrequently require urgent…
  • 2016 International Congress

    Self-perception of vocal handicap in Parkinson’s disease

    A.K. Silbergleit, J. Wall, L. Schultz, J. Peacock, P.A. LeWitt (West Bloomfield, MI, USA)

    Objective: The objective of this study was to evaluate self-perception of vocal handicap in individuals with Parkinson's disease at various stages of diagnosis. Background: The…
  • 2016 International Congress

    Therapeutic effect of onabotulinumtoxinA (BoNT/A) in hemifacial spasm and trigeminal neuralgia post Ramsay Hunt Syndrome type II

    R. López-Castellanos, R. López-Contreras (San Salvador, El Salvador)

    Objective: To evaluate the therapeutic and preventive effect of OnabotulinumtoxinA (BoNT/A) in the treatment of hemifacial spasm, bruxism, and trigeminal neuralgia post Ramsay Hunt Syndrome.…
  • 2016 International Congress

    Duration of levodopa treatment and prevalence of osteoporosis in patients with Parkinson’s disease

    S.H. Guptha (Peterborough, United Kingdom)

    Objective: To assess whether the prevalence of osteoporosis increases with the duration of levodopa treatment in patients with Parkinson's disease. Background: Patients with Parkinson's disease…
  • 2016 International Congress

    Participant feedback in the PREDICT-PD study

    C.W. Osborne, J. Bestwick, G. Giovannoni, A.J. Lees, A. Schrag, A. Noyce (London, United Kingdom)

    Objective: To explore the underlying motivation behind participation in PREDICT-PD and whether this had an influence on later drop out from the study. Background: The…
  • 2016 International Congress

    How accurate is the prediction of driving ability in a Parkinson’s clinic setting?

    C. Thomas, R. Amin, B. Mohamed (Cardiff, United Kingdom)

    Objective: To determine whether routine clinical assessment (motor examination, cognitive assessment and global clinical impression) accurately predicts the ability of People with Parkinson's (PwP) to…
  • 2016 International Congress

    Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

    E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard (Manchester, United Kingdom)

    Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of Pramipexole (PPX). Background: Parkinson's disease (PD) is characterized by both motor…
  • 2016 International Congress

    The effect of walking speed on postural stability in Parkinson’s disease fallers

    M.H. Cole, M. Sweeney, Z.J. Conway, T.D. Blackmore, P.A. Silburn (Virginia, Australia)

    Objective: This cross-sectional study aimed to evaluate the effect of imposed faster and slower walking speeds on gait rhythmicity in people with Parkinson's disease (PD)…
  • 2016 International Congress

    Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists

    S. Xu, J. Liu, X. Yang, Y. Qian, Q. Xiao (Shanghai, People's Republic of China)

    Objective: To investigate the association between dopamine receptor D types 2(DRD2) (CA)n and types 3 (DRD3) Ser9Gly polymorphisms and the risk of Parkinson's disease (PD),…
  • « Previous Page
  • 1
  • …
  • 87
  • 88
  • 89
  • 90
  • 91
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Life expectancy with and without Parkinson’s disease in the general population
    • An atypical and interesting feature of Parkinson´s disease
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley